April 12, 2006 — Novacea, Inc. today announced the initiation of ASCENT-2, its pivotal Phase 3 clinical study evaluating the combination of the Company’s novel oral anti-cancer agent, DN-101, and Taxotere® (docetaxel) in men with prostate cancer for whom hormonal therapy is no longer working, also known as androgen-independent prostate cancer (AIPC).

This randomized, controlled, multi-national study is seeking to enroll approximately 900 patients at over 125 medical centers in the United States, Europe, and Canada.
Full story:

http://www.psa-rising.com/wiredbird/novacea_0406.html